Trends in ALK inhibitors for non-small cell lung cancer.

e14046Background: Rearrangements in the gene encoding anaplastic lymphocyte kinase (ALK) are found in 3%–5% of patients. Treatment options have significantly expanded with ALK inhibitor drug approv...